PHILADELPHIA, March 19, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ('Century', NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)- derived cell therapies in autoimmune disease and cancer, today reported financial results and business highlights for the full year 2024. Clinical Pipeline for CNTY-101 Preclinical Pipeline Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 ...